The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. It has been found that the binding site of the surface antigen to the antibody plays an important role in viral replication, and when a mutation occurs in the site of the virus replication is significantly inhibited, and thus at least the HBV virus cannot cause a mutation in the region. In the present invention, using the virus obtained from the patient, it is confirmed that the antibody of the present invention binds to the hepatitis B virus YMDD mutant, which is produced using typical viral replication inhibitors, or HBsAg G14511 mutants, with which HBIG is isolated from plasma ( hepatitis B immunoglobulin does not bind. In addition, the in vivo effect of the antibodies of the present invention was studied using chimpanzees, which are unique animal models for hepatitis B. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in an in vivo model. Thus, it can be seen that the antibody of the present invention has the ability to bind not only to wild-type hepatitis B virus, but also to mutated hepatitis B viruses having the YMDD polymerase mutant and the G14511 mutation of surface antigen, as well as various mutant viruses, received from patients. Thus, the antibody of the present invention can be effectively used to prevent or treat infections caused not only by wild-type hepatitis B virus, but also by mutated hepatitis B viruses.В настоящем изобретении предлагается антитело, которое связывается с поверхностным антигеном (HBsAg) вируса гепатита В (HBV) для нейтрализации вируса гепатита В. Было обнаружено, что участок связывания поверхностного антигена с антителом играет важную роль в вирусной репликации, и при возникновении в участке мутации вирусная репликация значительно ингибируется, и, таким образом, по меньшей мере, вирус HBV не может вызывать мутацию в участке
